Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aslan Pharmaceutical Ltd (ASLN) ADS Each Rep 5 Ord Shares

Sell:$3.21 Buy:$3.23 Change: $0.02 (0.62%)
NASDAQ:0.11%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.21
Buy:$3.23
Change: $0.02 (0.62%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.21
Buy:$3.23
Change: $0.02 (0.62%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. The Company's ASLAN004 is a fully human monoclonal antibody targeting the IL-13 receptor a1 subunit (IL-13Ra1). By targeting IL-13Ra1, which forms the Type II receptor complex with IL-4Ra, ASLAN004 inhibits signaling of both interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheeze and cough.

Contact details

Address:
83 Clemenceau Avenue, #12-03 Ue Square

239920
Singapore
Telephone:
+65 (6) 2224235
Website:
aslanpharma.com/zh/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ASLN
ISIN:
US04522R1014
Market cap:
$217.60 million
Shares in issue:
348.09 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrew Howden
    Chairman of the Board
  • Carl Firth
    Chief Executive Officer, Director
  • Kiran Asarpota
    Vice President-Finance
  • Alison Ward
    Acting Vice President-R&D
  • Kenneth Kobayashi
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.